^
    3years
    Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Escalada de dosis de DF6002 en pacientes con tumores sólidos avanzados, y expansión en indicaciones seleccionadas. (clinicaltrialsregister.eu)
    P1/2, N=380, Ongoing, Dragonfly Therapeutics, Inc.
    Clinical • New P1/2 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • DF6002
    over3years
    Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications (clinicaltrials.gov)
    P1/2, N=380, Recruiting, Dragonfly Therapeutics | N=260 --> 380
    Clinical • Enrollment change • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • HER-2 negative • BRAF V600 • RET mutation • ER negative • PGR negative
    |
    Opdivo (nivolumab) • DF6002
    over3years
    [VIRTUAL] Preclinical characterization of DF6002/BMS-986415, a novel differentiated IL-12 Fc-fusion protein with robust antitumor activity as monotherapy or in combination with anti-PD-1 (AACR 2021)
    DF6002/BMS-986415, a novel IL-12 Fc-fusion protein, retained the full potency of rhIL-12 and showed improved exposure and tolerability; mDF6006 exhibited greater antitumor activity than rmIL-12. These data support the ongoing first-in-human phase 1/2 study evaluating DF6002/BMS-986415 as a novel therapeutic for the treatment of solid tumors in combination with nivolumab (NCT04423029).
    Preclinical • Combination therapy
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • DF6002